Abstract 327P
Background
Sentinel lymph node biopsy (SLNB) has been widely used to assess axillary staging. In clinical practice, it is crucial to define sentinel lymph node (SLN) and determine whether the detected nodes are SLNs during the process of SLNB. It is important to consider whether currently existing consensus on SLNB method which is dual-tracer technique may lead to the excessive and unnecessary removal of negative nodes. In addition, no uniform measurable and objective index has been established to define intra-operation palpable nodes, the excision of which may increase the random detection of SLN. The purpose of this study was to optimize the specific method of SLNB.
Methods
To propose an optimal cut-off value for “radioisotope+bule dye” dual-tracer method, the detailed information of (BC) patients who had no clinical node involvement and underwent SLNB from November 2010 to February 2021 was prospectively collected in the breast surgery department of West China Hospital. We analyzed the site and size, radioactivity, the status of blue dye and the pathological results of each node detected of each patients.
Results
A total of 4985 lymph nodes from 1595 BC patients were identified. Only 11.57% (577/4985) SLNs were defined as pathologically positive, resulting in 88.43% (4408/4985) negative nodes removed excessively. By gradually increasing the threshold of radioisotope count in comparison to the hottest SLN, we found that when elevating the cut-off value from 10% to approximately 60%, 17.3% of lymph nodes were spared removal, among which only 0.88% were missed positive SLNs. Raising the optimal cutoff value of radioisotopes to 60% and exempting palpable nodes at the same time could reduce the number of nodes detected by 30.81% with only 1.75% missed positive SLNs. Additionally, multivariate analysis in our study showed that larger tumor size and higher clinical N stage was significantly positively associated with SLN metastasis.
Conclusions
Raising the optimal cut-off value of radioisotope to 60% and exempting palpable nodes may be considered as a potential alternative method to avoid removing excessive negative nodes in SLNB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q. Lv.
Funding
West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02